

Report Title	Integrated Quality & Performance Report June 2020		
Sponsoring Executive	Dave Baker, Director of Partnerships and Innovation		
Report Author	Yasmina Gainer, Head of Performance and Costing		
Meeting	Trust Board	Date	6 th August 2020

1. Suggested discussion points *[two or three issues you consider the Trust Board should focus on]*

- The restoration and recovery plan remains paramount with a growing backlog, worsening RTT position and failing cancer performance with regards to diagnosis and urgent referral to treatment times. We are recovering to plan in some areas but not all. With safety the priority clinical need is being prioritised ahead of RTT performance.
- Still-birth rates increased for a third month running including adjusted perinatal mortality rate of 16.7 per 1000 babies. A report to the Q&S committee in July identified: no direct relationship to Covid 19; perinatal losses in line with prior two years despite the higher numbers in May and June; a number of actions to put in additional safeguards;
- There was one fall causing serious harm and two grade 4 pressure ulcers;
- On the persistent reds: Mandatory Training continues to improve nearing 90%: MRSA screening in non- elective areas nears target levels at 93% and Stroke Ward admissions within 4 hours achieves target for the first time since March 2019. The fractured neck of femur success in May did not sustain in June.
- Sickness rates are returning to normality having peaked at 8.3% in April, they now return to 5% in June which compares to 4.7% in June last year.

2. Alignment to 2020 Vision *[indicate with an 'X' which Plan this paper supports]*

Safety Plan	<input checked="" type="checkbox"/>	Public Health Plan	<input checked="" type="checkbox"/>	People Plan & Education Plan	<input checked="" type="checkbox"/>
Quality Plan	<input checked="" type="checkbox"/>	Research and Development		Estates Plan	
Financial Plan	<input checked="" type="checkbox"/>	Digital Plan		Other <i>[specify in the paper]</i>	

3. Previous consideration *[where has this paper been previously discussed?]*

OMC; WD5 Distribution to Groups; PMC; CLE; Q&S

4. Recommendation(s)

The Board is asked to:

- Note the performance for June 2020; Assure itself that performance of clinical indicators is in line with expectations or actions
- Assure itself that recovery will deliver to plan whilst focussing on clinical prioritisation and pro-actively managing long waits

5. Impact *[indicate with an 'X' which governance initiatives this matter relates to and where shown elaborate]*

Trust Risk Register	Y	Numerous					
Board Assurance Framework	X	SBAF 11: Labour Supply and SBAF 14: Amenable Mortality					
Equality Impact Assessment	Is this required?	Y		N	<input checked="" type="checkbox"/>	If 'Y' date completed	
Quality Impact Assessment	Is this required?	Y		N	<input checked="" type="checkbox"/>	If 'Y' date completed	